Search research articles
Contact Us
Filters
Showing results (61-70 of 262) with videos related to
Page
of 27
Sort By:
Hematological Oncology
|
April 23, 2024
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before
Jessica Saddi, Amelia Barcellini, Manuel Gotti, et al.
Research and Practice in Thrombosis and Haemostasis
|
March 31, 2023
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
Oscar Borsani, Virginia V Ferretti, Ilaria C Casetti, et al.
Annals of Hematology
|
September 6, 2025
Unicentric Castleman disease treated with rituximab before surgery: clinicopathologic findings
Marco Paulli, Giuseppe Neri, Francesca Antoci, et al.
Clinical Lymphoma & Myeloma
|
July 11, 2007
An insidious presentation of splenic marginal zone lymphoma
Sara Burcheri, Luca Arcaini, Matteo Della Porta, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 11, 2014
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)
Corrado Tarella, Luca Arcaini, Luca Baldini, et al.
Haematologica
|
January 29, 2003
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia
Francesco Passamonti, Lucia Malabarba, Ester Orlandi, et al.
American Journal of Hematology
|
August 20, 2009
Blast phase of essential thrombocythemia: A single center study
Francesco Passamonti, Elisa Rumi, Luca Arcaini, et al.
International Journal of Cancer
|
January 10, 2009
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection
Luca Arcaini, Cristiana Pascutto, Francesco Passamonti, et al.
Blood
|
September 28, 2013
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni, Silvia Zibellini, Luca Arcaini, et al.
Therapeutic Drug Monitoring
|
November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings
Mario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Page
of 27
Search research articles
Search
Showing results (61-70 of 262) with videos related to
Sort By:
Page
of 27
Hematological Oncology
|
April 23, 2024
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before
Jessica Saddi, Amelia Barcellini, Manuel Gotti, et al.
Research and Practice in Thrombosis and Haemostasis
|
March 31, 2023
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
Oscar Borsani, Virginia V Ferretti, Ilaria C Casetti, et al.
Annals of Hematology
|
September 6, 2025
Unicentric Castleman disease treated with rituximab before surgery: clinicopathologic findings
Marco Paulli, Giuseppe Neri, Francesca Antoci, et al.
Clinical Lymphoma & Myeloma
|
July 11, 2007
An insidious presentation of splenic marginal zone lymphoma
Sara Burcheri, Luca Arcaini, Matteo Della Porta, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 11, 2014
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)
Corrado Tarella, Luca Arcaini, Luca Baldini, et al.
Haematologica
|
January 29, 2003
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia
Francesco Passamonti, Lucia Malabarba, Ester Orlandi, et al.
American Journal of Hematology
|
August 20, 2009
Blast phase of essential thrombocythemia: A single center study
Francesco Passamonti, Elisa Rumi, Luca Arcaini, et al.
International Journal of Cancer
|
January 10, 2009
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection
Luca Arcaini, Cristiana Pascutto, Francesco Passamonti, et al.
Blood
|
September 28, 2013
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni, Silvia Zibellini, Luca Arcaini, et al.
Therapeutic Drug Monitoring
|
November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings
Mario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Page
of 27